Drug Discovery and Development
Drug development. Focus on obesity, Type II diabetes / metabolic syndrome, inflammatory diseases, and organ protection in severe cardiovascular diseases
Optimizing proteins
Replacement Capital October 2004
Replacement Capital October 2004
Rapid candidate drug generation for metabolic and inflammatory diseases
Acquired by Biovitrum (Sweden) August 2005
Acquired by Biovitrum (Sweden) August 2005
Human Antibodies - IPO
IPO Nordic Stock Exchange [BINV] June 2001
IPO Nordic Stock Exchange [BINV] June 2001
Prophylaxis and cure for allergic diseases
Bankruptcy, June 2009
Bankruptcy, June 2009
Development of innovative new cancer drugs based on a proprietary RNA antagonist technology
Therapeutics for topical treatment of acute and chronic pain. Several application areas including arthritis
Vaccines for veterinary and human use. Products on the veterinary market includes the adjuvant for the leading horse influenza vaccine.
Devices and Implants
Injectable bone substitute, used in osteporotic fractures
Chest compression devices for CPR procedures aimed at patients with sudden cardiac arrest
Physiocontrol, a subsidiary of Medtronic, acquired Jolife in February 2011
R&D tools
Human stem cells. Highly specialized cell lines for use in drug discovery and toxicology
Cellectis S.A, a French quoted Biotech company, acquired Cellartis in November 2011
Cost effective high throughput electro physiology. Computer controlled microfluidic chip-based system for patch-clamp-based ion channel drug screening
Other
Large scale protein separation and purification
Programs within rehabilitation, leadership, education and organizational development based on scientifically proven methods in cognitive behavioral therapy